Caribou Biosciences, Inc.
CRBU · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $9,994 | $34,477 | $13,851 | $9,598 |
| % Growth | -71% | 148.9% | 44.3% | – |
| Cost of Goods Sold | $3,927 | $3,525 | $3,641 | $984 |
| Gross Profit | $6,067 | $30,952 | $10,210 | $8,614 |
| % Margin | 60.7% | 89.8% | 73.7% | 89.7% |
| R&D Expenses | $130,153 | $112,075 | $82,230 | $52,255 |
| G&A Expenses | $46,457 | $38,461 | $38,020 | $0 |
| SG&A Expenses | $46,457 | $38,461 | $38,020 | $23,338 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$3,927 | -$3,525 | -$3,641 | $0 |
| Operating Expenses | $172,683 | $147,011 | $116,609 | $75,593 |
| Operating Income | -$166,616 | -$116,059 | -$106,399 | -$66,979 |
| % Margin | -1,667.2% | -336.6% | -768.2% | -697.8% |
| Other Income/Exp. Net | $17,502 | $14,182 | $7,048 | $377 |
| Pre-Tax Income | -$149,114 | -$101,877 | -$99,351 | -$66,602 |
| Tax Expense | -$9 | $193 | $70 | $321 |
| Net Income | -$149,105 | -$102,070 | -$99,421 | -$66,923 |
| % Margin | -1,491.9% | -296.1% | -717.8% | -697.3% |
| EPS | -1.65 | -1.38 | -1.64 | -1.11 |
| % Growth | -19.6% | 15.9% | -47.7% | – |
| EPS Diluted | -1.65 | -1.38 | -1.64 | -1.11 |
| Weighted Avg Shares Out | 90,318 | 73,808 | 60,801 | 60,263 |
| Weighted Avg Shares Out Dil | 90,318 | 73,808 | 60,801 | 60,263 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $10,700 | $4,600 | $148 |
| Interest Expense | $0 | $0 | $0 | $8 |
| Depreciation & Amortization | $3,927 | $3,525 | $3,641 | $984 |
| EBITDA | -$162,689 | -$112,534 | -$95,710 | -$65,610 |
| % Margin | -1,627.9% | -326.4% | -691% | -683.6% |